PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34663950-7	2021	CONCLUSION: We provide clinical evidence supporting the role of SLFN11 as a DDA therapy selection biomarker in SCLC and highlight the need for further clinical investigation into SLFN11 as a PARP inhibitor predictive biomarker.	dda	76-79	schlafen family member 11	Homo sapiens	64-70	
34549724-8	2021	In summary, we propose SLFN11 is a dual biomarker capturing simultaneously interconnected immunological and cancer cell-intrinsic functional dispositions associated with sensitivity to DDA treatment.	dda	185-188	schlafen family member 11	Homo sapiens	23-29	
33339894-3	2021	METHODS: We used a multidisciplinary effort combining specific immunohistochemistry, pharmacology tests, anticancer combination therapies and mechanistic studies to assess SLFN11 as a potential biomarker for stratification of patients treated with several DDA and/or DDRi in the preclinical and clinical setting.	dda	256-259	schlafen family member 11	Homo sapiens	172-178	
33339894-4	2021	RESULTS: SLFN11 protein associated with both preclinical and patient treatment response to DDA, but not to non-DDA or DDRi therapies, such as WEE1 inhibitor or olaparib in breast cancer.	dda	91-94	schlafen family member 11	Homo sapiens	9-15	
33339894-6	2021	Combinations of DDA with DDRi targeting the replication-stress response (ATR, CHK1 and WEE1) could re-sensitise SLFN11-absent/low cancer models to the DDA treatment and were effective in upper gastrointestinal and genitourinary malignancies.	dda	16-19	schlafen family member 11	Homo sapiens	112-118	
33339894-6	2021	Combinations of DDA with DDRi targeting the replication-stress response (ATR, CHK1 and WEE1) could re-sensitise SLFN11-absent/low cancer models to the DDA treatment and were effective in upper gastrointestinal and genitourinary malignancies.	dda	151-154	schlafen family member 11	Homo sapiens	112-118	
33339894-7	2021	CONCLUSION: SLFN11 informs on the standard of care chemotherapy based on DDA and the effect of selected combinations with ATR, WEE1 or CHK1 inhibitor in a wide range of cancer types and models.	dda	73-76	schlafen family member 11	Homo sapiens	12-18	
30374083-2	2018	Here, we show that SLFN11 preferentially inhibits translation of the serine/threonine kinases ATR and ATM upon DDA treatment based on distinct codon usage without disrupting early DNA damage response signaling.	dda	111-114	schlafen family member 11	Homo sapiens	19-25	
31222709-4	2019	SLFN11 has been reported as a predictive biomarker for DDA and PARP inhibitors in human neoplasms.	dda	55-58	schlafen family member 11	Homo sapiens	0-6